SAN DIEGO, Oct 16, 2012 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA),a leading hemp industry innovator and its CanChew Biotechnologies portfolio company have commenced market trial sign ups for the CanChew CBD chewing gum product line. The free market trial offer is open to patients suffering from pain from MS Muscular Spasticity, Cancer, Neuropathic Conditions, Psychological/Mood Disorders and Arthritis. The trial will be managed by CanChew Directors: Dr. George Anastassov, Dr. Philip A. Van Damme, and Production Specialist Lekhram Changoer. The sign-up period is underway and will last until November 15th or until all of the participant slots are filled.
Since announcing the trial on October 1, the company has received terrific feedback from many qualifying patient participants and looks forward to a strong program.
For more information about the trial qualifications and registration, please visit http://canchewbiotech.com/ and click on the “Join Our Free Trial” link. Prospective patients are now able to log into a dedicated website and answer questions on a health history survey to determine their eligibility. Patients who qualify for the trial will receive a minimum one-month supply of the CBD chewing gum, which contains approximately 8-10 milligrams of CBD per piece and will be blister packed in packages of 8 and 32 pieces. Patients will provide specific feedback to the Company regarding usage and experience. While the company has been underway with clinical development for many months, it expects to launch human Clinical trials for this product and other CBD containing products by the end of 2013. CanChew Biotechnologies expects to launch over-the-counter retail sales of the product in early 2013.
The CBD health and wellness industry is estimated by MJNA to be a $5 billion market.
According to BCC Research and Market Forecasting, the global market for pain management pharmaceuticals and devices amounted to $19.1 billion in 2008 and is expected to increase to $32.8 billion in 2013. The compound annual growth rate (CAGR) for the 5-year period is projected at 11.5%.
“We have seen a tremendous number of inquiries this month from qualifying patients for the CanChew market trial. We look forward to a successful program. This news is especially encouraging as we continue to prepare for our full blown national and international CanChew launch in early 2013,” stated Ted Caligiuri, Interim President of Medical Marijuana, Inc.
About CanChew Biotech
CanChew® is a unique, socially acceptable, patient friendly, taste masked and convenient delivery format for delivery of cannabis/cannabinoid(s) based pharmaceuticals. The delivery of these medications via the oral mucosa provides for rapid and near complete absorption directly into the systemic circulation. This leads to rapid onset of effects and increased bioavailability. Pre-systemic metabolism is thus avoided. This system of delivery offers clearly improved economic opportunities compared to alternative drug delivery routes. For more information visit: http://www.canchewbiotech.com.
About Medical Marijuana,Inc.
Our mission is to be the premier hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value.
Medical Marijuana Inc. does not grow, sell or distribute any substances that violate United States Law or the controlled substance act.
For more information, please visit the company’s website at: www.MedicalMarijuanaInc.com
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration (FDA). These products and statements are not intended to diagnose, treat, cure, or prevent any disease.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
Investor Relations Contact:
Stuart T. Smith